Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx.

Clinical and translational radiation oncology

Hauswald H, Jensen AD, Krauss J, Haselmann R, Lossner K, Hartmann S, Windemuth-Kieselbach C, Münter MW, Debus J.
PMID: 30370340
Clin Transl Radiat Oncol. 2018 Sep 21;13:64-73. doi: 10.1016/j.ctro.2018.09.005. eCollection 2018 Nov.

PURPOSE: This phase II trial was designed to evaluate efficacy and safety of a highly intensified therapy in locally advanced squamous cell carcinoma of the oro-, hypopharynx and larynx.METHODS: In this prospective, mono-centric, open-label, non-randomized phase II trial the...

Cite
Hauswald H, Jensen AD, Krauss J, et al. Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clin Transl Radiat Oncol. 2018;13:64-73doi: 10.1016/j.ctro.2018.09.005.
Hauswald, H., Jensen, A. D., Krauss, J., Haselmann, R., Lossner, K., Hartmann, S., Windemuth-Kieselbach, C., Münter, M. W., & Debus, J. (2018). Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clinical and translational radiation oncology, 1364-73. https://doi.org/10.1016/j.ctro.2018.09.005
Hauswald, H, et al. "Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx." Clinical and translational radiation oncology vol. 13 (2018): 64-73. doi: https://doi.org/10.1016/j.ctro.2018.09.005
Hauswald H, Jensen AD, Krauss J, Haselmann R, Lossner K, Hartmann S, Windemuth-Kieselbach C, Münter MW, Debus J. Phase II study of induction chemotherapy with docetaxel, cisplatin, 5-fluorouracil followed by radioimmunotherapy with cetuximab and intensity-modulated radiotherapy in combination with a carbon ion boost for locally advanced tumors of the oro-, hypopharynx and larynx. Clin Transl Radiat Oncol. 2018 Sep 21;13:64-73. doi: 10.1016/j.ctro.2018.09.005. eCollection 2018 Nov. PMID: 30370340; PMCID: PMC6199783.
Copy Download .nbib Format: NLM
Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance.

Breast care (Basel, Switzerland)

Jackisch C, Kreienberg R, Blettner M, Harbeck N, Lück HJ, Haidinger R, Schmitt DC, Schulte H, Windemuth-Kieselbach C, Zaun S, Hadji P.
PMID: 32774217
Breast Care (Basel). 2020 Jun;15(3):236-245. doi: 10.1159/000500771. Epub 2019 Sep 25.

BACKGROUND: Breast cancer patients' self-understanding of their disease can impact their quality of life (QoL); the relationship between compliance and QoL is poorly understood.PATIENTS AND METHODS: The Patient's Anastrozole Compliance to Therapy (PACT) program, a prospective, randomized study, investigated...

Cite
Jackisch C, Kreienberg R, Blettner M, et al. Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance. Breast Care (Basel). 2019;15(3):236-245doi: 10.1159/000500771.
Jackisch, C., Kreienberg, R., Blettner, M., Harbeck, N., Lück, H. J., Haidinger, R., Schmitt, D. C., Schulte, H., Windemuth-Kieselbach, C., Zaun, S., & Hadji, P. (2020). Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance. Breast care (Basel, Switzerland), 15(3), 236-245. https://doi.org/10.1159/000500771
Jackisch, Christian, et al. "Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance." Breast care (Basel, Switzerland) vol. 15,3 (2020): 236-245. doi: https://doi.org/10.1159/000500771
Jackisch C, Kreienberg R, Blettner M, Harbeck N, Lück HJ, Haidinger R, Schmitt DC, Schulte H, Windemuth-Kieselbach C, Zaun S, Hadji P. Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance. Breast Care (Basel). 2020 Jun;15(3):236-245. doi: 10.1159/000500771. Epub 2019 Sep 25. PMID: 32774217; PMCID: PMC7383248.
Copy Download .nbib Format: NLM
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.

Breast care (Basel, Switzerland)

Harbeck N, Blettner M, Hadji P, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Haidinger R, Schmitt D, Schulte H, Nitz U, Kreienberg R.
PMID: 24419247
Breast Care (Basel). 2013 May;8(2):110-20. doi: 10.1159/000350777.

BACKGROUND: The Patient's Anastrozole Compliance to Therapy (PACT) program is a large randomized study designed to assess whether the provision of educational materials (EM) could improve compliance with aromatase inhibitor therapy in postmenopausal women with early, hormone receptor-positive breast...

Cite
Harbeck N, Blettner M, Hadji P, et al. Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Breast Care (Basel). 2013;8(2):110-20doi: 10.1159/000350777.
Harbeck, N., Blettner, M., Hadji, P., Jackisch, C., Lück, H. J., Windemuth-Kieselbach, C., Zaun, S., Haidinger, R., Schmitt, D., Schulte, H., Nitz, U., & Kreienberg, R. (2013). Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Breast care (Basel, Switzerland), 8(2), 110-20. https://doi.org/10.1159/000350777
Harbeck, Nadia, et al. "Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer." Breast care (Basel, Switzerland) vol. 8,2 (2013): 110-20. doi: https://doi.org/10.1159/000350777
Harbeck N, Blettner M, Hadji P, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Haidinger R, Schmitt D, Schulte H, Nitz U, Kreienberg R. Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Breast Care (Basel). 2013 May;8(2):110-20. doi: 10.1159/000350777. PMID: 24419247; PMCID: PMC3683950.
Copy Download .nbib Format: NLM
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF.

European journal of cancer (Oxford, England : 1990)

Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Göppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D.
PMID: 34655839
Eur J Cancer. 2021 Oct 13;158:72-84. doi: 10.1016/j.ejca.2021.09.011. Epub 2021 Oct 13.

BACKGROUND: Combination of immune checkpoint inhibitors and mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) has been proposed to enhance the durability of anti-tumour responses induced by MAPKi. Here, we present phase I safety results from an open-label, phase I/II...

Cite
Zimmer L, Livingstone E, Krackhardt A, et al. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. Eur J Cancer. 2021;158:72-84doi: 10.1016/j.ejca.2021.09.011.
Zimmer, L., Livingstone, E., Krackhardt, A., Schultz, E. S., Göppner, D., Assaf, C., Trebing, D., Stelter, K., Windemuth-Kieselbach, C., Ugurel, S., & Schadendorf, D. (2021). Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. European journal of cancer (Oxford, England : 1990), 15872-84. https://doi.org/10.1016/j.ejca.2021.09.011
Zimmer, Lisa, et al. "Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF." European journal of cancer (Oxford, England : 1990) vol. 158 (2021): 72-84. doi: https://doi.org/10.1016/j.ejca.2021.09.011
Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Göppner D, Assaf C, Trebing D, Stelter K, Windemuth-Kieselbach C, Ugurel S, Schadendorf D. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF. Eur J Cancer. 2021 Oct 13;158:72-84. doi: 10.1016/j.ejca.2021.09.011. Epub 2021 Oct 13. PMID: 34655839.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries